Catalyst Biosciences, Inc.
Overview
Proteases are naturally occurring protein-degrading enzymes that regulate a wide variety of biological processes. Catalyst will harness the power of these enzymes as bio-pharmaceuticals by redirecting them to degrade specific proteins that promote disease. Catalyst calls these engineered protease therapeutics "Alterases ". Our technology consists of methods to identify proteases with tailor-made specificity. These designed proteases represent an exciting new modality in protein therapeutics. Alterases have the potential to be very powerful therapeutics due to their catalytic nature. Unlike standard small molecule or antibody drugs, a single protease molecule can inactivate hundreds to thousands of target molecules, resulting in higher efficacy and lowered dosing.
Corporate Structure
CHIEF EXECUTIVE OFFICER
TOP EXECUTIVES
Bryant EFong consultant
Christopher Thanos
James A. Wells Board of Directors
Charles S Craik Founder
Kevan Shokat
Sandra Waugh Ruggles
Donald G. Payan
Edwin L Madison Chief Scientific Officer
G. Steven Burrill Board of Directors
Ralph E. Christoffersen Board of Directors
Harold E. Selick Chairman
David O'Reilly President of Catalyst
Jack Nguyen
Roger Thomas Vice President, Preclinical Research
Augustine Lawlor Managing Director of Healthcare Ventures
Marc Navre Vice President, Drug Discovery
Camille Deluca-Flaherty Vice President, Project Management
Tad Thomas Senior Director, Process Development and Manufacturing
Erik Wiberg Chief Financial Officer
Jeffrey R. Latts Chief Medical Advisor
Shaun Coughlin Board of Directors
Marc Pelletier Board of Directors
Barry Selick Board of Directors
David Ginsburg Board of Directors
Gerardo Zapata Vice President, Process Development and Manufacturing
Asish K Xavier Board of Directors
Gregory Stahl Board of Directors
Robert J Fletterick Board of Directors
Guy S Salvesen Board of Directors
Todd J Lorenz Chief Medical Officer
